Table 2.
Prevalence of genetic and epigenetic alteration in the different subtypes of serrated polyps by combining all comparable data from [73, 75–84].
Polyp type | BRAF mutation | KRAS mutation | CIMP-H* | MLH1 methylation | MGMT methylation |
---|---|---|---|---|---|
HP | |||||
Microvesicular | 66.3% | 12.3% | 47.4% | 39.5% | 26.3% |
Goblet-cell | 20% | 48.4% | 14.3% | 14.3% | 0% |
All subtypes | 51.5% | 22.1% | 38.5% | 27% | 14.8% |
SSA/P | 83.9% | 5.8% | 75.9% | 42.6% | 25% |
TSA | 62.5% | 22.4% | 79.3% | 47.5% | 74.2% |